Comparison of obinutuzumab and rituximab for treating neuropsychiatric lupus: a retrospective case-control study.

ABSTRACT:

Objectives

Neuropsychiatric SLE (NPSLE) lacks evidence-based treatment strategies. This study compared the effectiveness and safety profiles of obinutuzumab (OBZ) and rituximab (RTX) in patients with NPSLE.

Methods

Patients with new-onset NPSLE meeting British Isles Lupus Assessment Group grade A criteria who received either OBZ or RTX between 2018 and 2024 at Renji Hospital, Shanghai Jiao Tong University School of Medicine (with ≥12 months follow-up) were included. Propensity score matching (1:2 ratio) based on age, sex and SLE Disease Activity Index (SLEDAI) was performed. The primary outcome was complete or partial response at 12 months. Kaplan-Meier curves compared therapeutic effectiveness. Safety profiles of OBZ and RTX were recorded.

Results

27 patients with ne

SUBMITTER: Wang H 

PROVIDER: S-EPMC12587898 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature